BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Heart
,
Anticancer prodrugs
,
Lipitor
,
rs2230926
,
IL1A
,
cell-cell adhesion
,
Leukemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
receptors erythropoietin
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Drug target sets for approved compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
Novel mutations in EPO-R and oxygen-dependent degradation (ODD) domain of EPAS1 genes-a causative re…
Update on the role and mechanism of erythropoietin receptor in acute kidney injury and repair or fib…
Erythropoietin and Soluble Erythropoietin Receptor: A Role for Maternal Vascular Adaptation to High-…
Low incidence of EPOR mutations in idiopathic erythrocytosis.
Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-eryt…
Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens
A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis P…
Erythropoietin Therapy for Subarachnoid Hemorrhage
Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ